EDWARD CLARK: Open Payments
NPI 1225268907 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$738 in 34 payments from 9 companies in 2025. Trend: 2023 $24 · 2024 $139 · 2025 $738
Food & beverage: $738
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $121 |
| Axsome Therapeutics, Inc. | 5 | $121 |
| Janssen Pharmaceuticals, Inc | 5 | $116 |
| Lundbeck LLC | 5 | $102 |
| Otsuka America Pharmaceutical, Inc. | 5 | $91 |
| Bausch Health US, LLC | 4 | $71 |
| Neurocrine BioSciences, Inc. | 2 | $54 |
| ABBVIE INC. | 2 | $39 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
Products named: REXULTI, CAPLYTA, Auvelity, SPRAVATO, WELLBUTRIN, INGREZZA, VRAYLAR, COBENFY.
Industry payments across TX — which companies pay providers there.
